Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqGS - Nasdaq Real Time Price USD

Moderna, Inc. (MRNA)

Compare

31.12

-1.00

(-3.11%)

At close: March 28 at 4:00:01 PM EDT

31.20

+0.08

+(0.26%)

After hours: March 28 at 7:59:52 PM EDT

Jim Cramer Slams Moderna, Inc. (MRNA) as One of the Year’s Biggest Disappointments

We recently published a list of Jim Cramer Discussed These 9 Stocks Recently. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other stocks that Jim Cramer discussed. On Wednesday, Jim Cramer, the host of Mad Money, took a closer look at the state of the market […]

Insider Monkey yesterday

MRNA
-3.11%
China Expansion Helps Fuel This AI-Powered Cloud Stock In Rough Market

Boosted by partnerships with Big Pharma and a push into China, Veeva continues to battle to break out in troubled market.

Investor's Business Daily 2 days ago

GLAXF

GSK

VEEV
Jim Cramer: Moderna (MRNA) Blew It – But Their Cash Pile Could Save Them!

We recently published a list of Did Jim Cramer Nail or Miss These 14 Stocks? In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other stocks that Jim Cramer discusses. During the most recent episode of Mad Money, Jim Cramer described the current stock market as a […]

Insider Monkey 3 days ago

MRNA
-3.11%
Is Moderna Stock A Sell As RFK Jr. Reportedly Mulls A Massive Funding Pull?

Moderna stock skidded on reports Robert F. Kennedy Jr. is considering pulling funding for its bird flu vaccine. Is MRNA stock a sell?

Investor's Business Daily 3 days ago

MRNA
-3.11%
Moderna, Inc. (MRNA): Among Stocks To Trade Without Tariffs And Interest Rate Fears

We recently published a list of 10 Stocks To Trade Without Tariffs And Interest Rate Fears. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other stocks to trade without tariffs and interest rate fears. The Federal Reserve this week decided to keep interest rates unchanged, causing […]

Insider Monkey 3 days ago

MRNA
-3.11%
As Vaccine Skepticism Mounts, Moderna’s Business Grows More Precarious

Just a few years since pioneering a Covid-19 vaccine, Moderna faces a hostile political environment and a looming patent problem.

Barrons.com 4 days ago

MRNA
-3.11%
^GSPC

ABUS
Is Moderna, Inc. (MRNA) a Promising Biotech Stock According to Wall Street Analysts

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Moderna, Inc. (NASDAQ:MRNA) stands against other biotech stocks. Biotech Sector Set for Growth Amid Innovation and Investor Interest The biotechnology sector is gaining new momentum with better market […]

Insider Monkey 5 days ago

MRNA
-3.11%
Moderna, Inc. (MRNA): Among Stocks with Potential to Explode in 2025

We recently published a list of 10 Stocks with Potential to Explode in 2025. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other stocks with potential to explode in 2025. The recent pullback in US equities can be a sign of an aging bull market and […]

Insider Monkey 6 days ago

MRNA
-3.11%
Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst performers in the therapeutics industry.

StockStory 6 days ago

MRNA
-3.11%
BMRN

SRPT
Moderna price target lowered to $33 from $40 at JPMorgan

JPMorgan analyst Jessica Fye lowered the firm’s price target on Moderna (MRNA) to $33 from $40 and keeps an Underweight rating on the shares, primarily due to more conservative RSV and influenza estimates. The firm now models 2025 RSV sales of about $148M, versus a prior estimate of about $210M, and for FY25 it now models total revenue of $2.1B, versus consensus of $2.2B and just above the $2B guidance midpoint, the analyst tells investors. Published first on TheFly – the ultimate source for rea

TipRanks 8 days ago

MRNA
-3.11%
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move

Here's why they think Altimmune (NASDAQ: ALT), Moderna (NASDAQ: MRNA), and Pfizer (NYSE: PFE) are dirt cheap now, and why buying these value stocks could be a brilliant move. David Jagielski (Altimmune): If you want to swing for the fences, one underrated GLP-1 weight loss drug company you'll want to consider investing in right now is Altimmune. It's not the safest healthcare stock to own as there's no guarantee of how well its GLP-1 drug candidate, pemvidutide, will perform in late-stage trials, but its clinical results so far have been promising.

Motley Fool 8 days ago

MRNA
-3.11%
PFE
+0.80%
Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It

Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks 9 days ago

MRNA
-3.11%
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers.

StockStory 9 days ago

BMRN

GILD
+0.57%
MRNA
-3.11%
4 Things You Need to Know if You Buy Moderna Stock Today

It's been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine playing a landmark role in tackling the global pandemic in late 2020. Despite its generating record sales and profits through 2022, early projections of sustained demand for coronavirus vaccinations failed to materialize, leading to a sharp drop in the business. Here are five things you should know if you're considering buying Moderna stock now.

Motley Fool 10 days ago

MRNA
-3.11%
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season.

StockStory 10 days ago

BIIB

BMRN

MRNA
-3.11%
2 No-Brainer Biotech Stocks to Buy Right Now

Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock might soar as investors bet on the company's cutting-edge technology through its development stages -- and the stock could continue to gain after that company moves into the product commercialization stage. Once biotech products reach the marketplace, biotech companies benefit just like pharma companies from the following: Patients need their treatments regardless of the general economic environment, and this translates into a certain level of revenue for these players.

Motley Fool 11 days ago

MRNA
-3.11%
CRSP
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack

Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season.

StockStory 11 days ago

VRTX

BMRN

MRNA
-3.11%
Vaccine makers face mRNA backlash as states seek further restrictions

A handful of states are targeting the technology at the same time the Trump administration is cutting research funding and revoking vaccine contracts.

Pharma Voice 11 days ago

MRNA
-3.11%
Moderna Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?

Given the uncertainty around its top-line growth, short-term investors should exercise caution when investing in MRNA stock.

Zacks 12 days ago

MRNA
-3.11%
Moderna (MRNA) Advances But Underperforms Market: Key Facts

In the latest trading session, Moderna (MRNA) closed at $34.71, marking a +0.26% move from the previous day.

Zacks 13 days ago

MRNA
-3.11%

Performance Overview

Return	MRNA	S&P 500 (^GSPC)
YTD	-25.16%	-5.11%
1-Year	-70.80%	+6.22%
3-Year	-82.02%	+21.97%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Moderna, Inc. (MRNA)

Jim Cramer Slams Moderna, Inc. (MRNA) as One of the Year’s Biggest Disappointments

China Expansion Helps Fuel This AI-Powered Cloud Stock In Rough Market

Jim Cramer: Moderna (MRNA) Blew It – But Their Cash Pile Could Save Them!

Is Moderna Stock A Sell As RFK Jr. Reportedly Mulls A Massive Funding Pull?

Moderna, Inc. (MRNA): Among Stocks To Trade Without Tariffs And Interest Rate Fears

As Vaccine Skepticism Mounts, Moderna’s Business Grows More Precarious

Is Moderna, Inc. (MRNA) a Promising Biotech Stock According to Wall Street Analysts

Moderna, Inc. (MRNA): Among Stocks with Potential to Explode in 2025

Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

Moderna price target lowered to $33 from $40 at JPMorgan

Buying These Dirt-Cheap Stocks Could Be a Brilliant Move

Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

4 Things You Need to Know if You Buy Moderna Stock Today

Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

2 No-Brainer Biotech Stocks to Buy Right Now

A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack

Vaccine makers face mRNA backlash as states seek further restrictions

Moderna Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?

Moderna (MRNA) Advances But Underperforms Market: Key Facts

Performance Overview